Enliven Therapeutics Inc（ELVN）の株式分析ELVNEnliven Therapeutics Inc

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Enliven Therapeutics is currently trading at $57.86, which is below the average analyst price target of $75, indicating potential upside. However, the RSI is at 31.61, suggesting the stock is oversold, and the company has reported consistent net losses, with Q2 EPS at -0.49, missing expectations. The main risk is the ongoing negative earnings trend, with a projected net income loss of approximately $32 million for Q2 2026.